Tom Baker Cancer Centre & University of Calgary, 1331-29th St NW, Calgary, Alberta, Canada.
Expert Opin Biol Ther. 2012 Mar;12(3):343-51. doi: 10.1517/14712598.2012.657622. Epub 2012 Jan 28.
Targeted therapy against CD20 with the mAb rituximab has led to significant improvements in survival for patients with B-cell non-Hodgkin's lymphoma (NHL). Despite these improvements, many patients relapse and/or become refractory after rituximab-containing therapies and thus better therapies are required for NHL.
Obinutuzumab is a novel, humanized, anti-CD20 mAb currently being investigated in Phase III studies in comparison to rituximab. An overview of obinutuzumab, its mechanisms of action and the results of pre-clinical and Phase I/II studies are presented.
Pre-clinical studies suggest that obinutuzumab is a more potent anti-CD20 mAb than Rituximab at inducing antibody-dependent cellular cytotoxicity (ADCC) and direct cell death (DCD). Obinutuzumab is safe and effective in CD20 + NHL and further study is warranted. Results of ongoing Phase III clinical trials comparing Obinutuzumab to Rituximab in different disease settings and with different chemotherapy regimens are eagerly awaited.
针对 CD20 的靶向治疗药物美罗华（利妥昔单抗）显著改善了 B 细胞非霍奇金淋巴瘤（NHL）患者的生存。尽管取得了这些进展，但许多患者在接受利妥昔单抗为基础的治疗后复发和/或产生耐药性，因此需要更好的 NHL 治疗方法。
奥滨尤妥珠单抗是一种新型人源化抗 CD20 mAb，目前正在进行 III 期临床试验，与利妥昔单抗进行比较。本文对奥滨尤妥珠单抗进行了概述，介绍了其作用机制，以及临床前和 I/II 期研究结果。
临床前研究表明，奥滨尤妥珠单抗在诱导抗体依赖性细胞毒性（ADCC）和直接细胞死亡（DCD）方面比利妥昔单抗更有效。奥滨尤妥珠单抗在 CD20 + NHL 中安全有效，进一步的研究是必要的。正在进行的 III 期临床试验结果比较了奥滨尤妥珠单抗与利妥昔单抗在不同疾病环境和不同化疗方案中的疗效，目前正在热切期待。
